How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?

作者信息

Zhou Fei, Chen Xiaoxia, Zhou Caicun

机构信息

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, People's Republic of China.

出版信息

J Thorac Oncol. 2014 Feb;9(2):e19-20. doi: 10.1097/JTO.0000000000000046.

DOI:10.1097/JTO.0000000000000046

PMID:24419431

Abstract

摘要

相似文献

How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?

J Thorac Oncol. 2014 Feb;9(2):e19-20. doi: 10.1097/JTO.0000000000000046.

How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?

J Thorac Oncol. 2014 Feb;9(2):e20. doi: 10.1097/JTO.0000000000000098.

How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?

J Thorac Oncol. 2013 Jan;8(1):89-95. doi: 10.1097/JTO.0b013e31827690b5.

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.

Oncotarget. 2017 Jul 25;8(30):49680-49688. doi: 10.18632/oncotarget.17915.

Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9990-5. doi: 10.1073/pnas.1510837112. Epub 2015 Jul 27.

[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):323-8.

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.

J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.

J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

J Thorac Oncol. 2013 Jul;8(7):892-8. doi: 10.1097/JTO.0b013e31828c3929.

引用本文的文献

[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):283-290. doi: 10.3779/j.issn.1009-3419.2024.101.07.

A Proposal to Reflect Survival Difference and Modify the Staging System for Lung Adenocarcinoma and Squamous Cell Carcinoma: Based on the Machine Learning.

Front Oncol. 2019 Aug 14;9:771. doi: 10.3389/fonc.2019.00771. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验